At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KURE KraneShares MSCI All China Health Care Index ETF
Post-Mkt 08-24 18:34:45 EDT
18.62
-0.49
-2.58%
盘后18.60
-0.02-0.09%
18:20 EDT
High18.69Low18.50Vol48.67K
Open18.64D1 Closing19.11Amplitude0.99%
Mkt Cap107.99MTradable Cap107.99MTotal Shares5.80M
T/O904.82KT/O Rate0.84%Tradable Shares5.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Transcenta Holding Announces Extraordinary General Meeting
Reuters  ·  29 minutes ago
Transcenta Holding Announces Extraordinary General Meeting
Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition
Reuters  ·  08-24 19:34
Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition
WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion
Reuters  ·  08-24 19:22
WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy
MT Newswires Live  ·  08-24 19:12
Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy
CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors
Dow Jones  ·  08-24 16:32
CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors
Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong
Dow Jones  ·  08-24 16:30
Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong
Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results
Stock News  ·  08-24 15:46
Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results
BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating
Deep News  ·  08-23 12:50
BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating
UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating
Deep News  ·  08-23 12:40
UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating
Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance
Deep News  ·  08-23 12:30
Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance
CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Simply Wall St.  ·  08-23 08:56
CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution
Reuters  ·  08-21
China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution
TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million
Reuters  ·  08-21
TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million
UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50
MT Newswires Live  ·  08-21
UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50
Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating
Stock News  ·  08-21
Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating
Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong
Dow Jones  ·  08-21
Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong
CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors
Dow Jones  ·  08-21
CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors
美银证券上调石药集团目标价至8.6港元，维持“跑输大市”评级
Stock News  ·  08-21
美银证券上调石药集团目标价至8.6港元，维持“跑输大市”评级
Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors
Reuters  ·  08-21
Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors
Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
THOMSON REUTERS  ·  08-21
Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
No data available

Introduction

Company Name.
KraneShares MSCI All China Health Care Index ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its underlying index or in instruments that have economic characteristics similar to those in the underlying index. The underlying index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint, which is designed to measure the equity market performance of Chinese companies in the healthcare sector. The fund is non-diversified.
Issue price:
--